• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

  • Nov 21 2024
  • Duración: 19 m
  • Podcast

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

  • Resumen

  • Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.